UNICYCIVE THERAPEUTICS INC. - COMMON STOCK

0,5800

30-января-25 15:45:00

15 мин. задержка

Акции

+0,0498

+9,39%

Сегодняшний диапазон

0,5210 - 0,5800

ISIN

N/A

Источник

NASDAQ

Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

28 янв 2025 06:00:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

07 янв 2025 06:00:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics

17 дек 2024 06:00:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

21 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

13 ноя 2024 06:15:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

11 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

28 окт 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

16 окт 2024 15:35:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

14 окт 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

09 окт 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

24 сен 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

16 сен 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 сен 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

03 сен 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024

26 авг 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update

14 авг 2024 06:10:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)

17 июл 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

11 июл 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

10 июл 2024 06:03:00 Источник Nasdaq GlobeNewswire
Unicycive Therapeutics Joins Russell Microcap® Index

01 июл 2024 06:03:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.